BioIVT recently ran an industry survey to help them understand what the current industry standards are for when and why researchers are running various Absorption, Distribution, Metabolism, and Excretion (ADME) studies, including Drug Metabolism and Pharmacokinetics (DMPK) and Drug-Drug Interaction (DDI) research. With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these.

Take a look at the infographic to read about when most researchers are performing ADME/PK & DDI testing, see what the top 4 repercussions and risks are from postponing, and the top 3 benefits to running more ADME testing during preclinical research.